The 8th JSH International Symposium 2017 in Miyazaki

Date:
Friday, 19 May, - Saturday, 20 May, 2017
Venue:
Seagaia Convention Center in Miyazaki
Theme:
Cell and Gene Therapy for Hematological Disorders -Current Status, Challenges, and Future Perspectives-

Program

Program at a Glance

Friday, 19 May, 2017
8:30-9:50

Asian Session
Current Cell and Gene Therapy in Asia

10:00-10:40

Special Lecture I
Advanced Genetic Engineering of Hematopoiesis to Treat Inherited Diseases

10:40-11:20

Special Lecture II
CAR Therapy: the CD19 paradigm.

11:30-12:30

Luncheon Seminar

Luncheon Seminar 1
Co-sponsored by Nippon Shinyaku Co.,Ltd
Luncheon Seminar 2
Co-sponsored by Bristol-Myers Squibb K.K.
12:30-13:20

Poster Session

13:20-15:00

JSH-EHA Joint Session
Hematopoietic Stem Cell Gene Therapy for Congenital Disorders

15:00-15:40

Special lecture III
Immunotherapy for Hematologic Malignancies; B Cells and Beyond

16:00-17:40

Plenary Session I
Current Cell and Gene Therapy

17:40-18:10

Oral Presentation from Poster Presentation

Reception
Saturday, 20 May, 2017
8:00-9:40

Plenary Session II
New Horizon of Stem Cell Transplantation

9:40-10:20

Special lecture IV
Gene Therapy for Hemophilia

10:30-12:10

JSH-ASH Joint Session
Next Generation of Cell and Gene Therapy

12:20-13:20

Luncheon Seminar

Luncheon Seminar 3
Co-sponsored by
Ono Pharmaceutical Co., Ltd. and
Bristol-Myers Squibb K.K.
Luncheon Seminar 4
Co-sponsored by Novartis Pharma K.K.


Program

Friday, 19 May, 2017
8:30-9:50
Asian Session Current Cell and Gene Therapy in Asia
Current Situation of Cell Therapy in China
Dr. Kaiyan Liu (Peking University People's Hospital, China)
T Cell Immunotherapy for EBV-associated Tumor and CMV Reactivation
Dr. Seok-Goo Cho
(Seoul St. Mary Hospital, College of Medicine, The Catholic University of Korea, Korea)
Novel Technology of CAR-T Cell Therapy for Treatment of Solid Tumors
Dr. Koji Tamada (Yamaguchi University Graduate school of Medicine,
The Institute of Medical Science, The University of Tokyo)
Haploidentical Allogeneic Stem Cell Transplant in Severe Thalassemia Patients
Dr. Suradej Hongeng (Ramathibodi Hospital, Mahidol University, Thailand)
9:50-10:00 Break
10:00-10:40
Special Lecture I
Advanced Genetic Engineering of Hematopoiesis to Treat Inherited Diseases
Dr. Luigi Naldini (San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Italy)
10:40-11:20
Special Lecture II
CAR therapy: the CD19 paradigm.
Dr. Michel Sadelain (Memorial Sloan Kettering Cancer Center, USA)
11:20-11:30 Break
11:30-12:30

Luncheon Seminar 1 (Co-sponsored by Nippon Shinyaku Co.,Ltd.)

Dr. Raphael Itzykson (Hôpital Saint-Louis, France)

11:30-12:30

Luncheon Seminar 2 (Co-sponsored by Bristol-Myers Squibb K.K.)

Dr. Ichiro Hanamura (Aichi Medical University Hospital)

12:30-13:20 Poster Session
13:20-15:00
JSH-EHA Joint Session
Hematopoietic Stem Cell Gene Therapy for Congenital Disorders
SCID Gene Therapy Including WAS
Dr. Adrian Thrasher (UCL Great Ormond Street Institute of Child Health, UK)
Stem Cell Ggene Therapy for WAS and Other Disorders
Dr. Christoph Klein (Hauner Children's Hospital ,Ludwig-Maximilian University Munich, Germany)
Gene Therapy for Immune Deficiency in Japan
Dr. Masafumi Onodera (Department of Human Genetics)
Hematopoietic Cell Therapy for Genetic Disorders with Impaired Immune Systems
Dr. Tomohiro Morio (Tokyo Medical and Dental University)
15:00-15:40
Special Lecture III
Immunotherapy for Hematologic Malignancies; B Cells and Beyond
Dr. Malcolm Brenner (Center for Cell and Gene Therapy, Baylor College of Medicine, USA)
15:40-16:00 Break
16:00-17:40
Plenary Session I "Current Cell and Gene Therapy"
Gene and Cell-based Medicinal Products in the European Union: Experience and Support
by the European Medicines Agency and its Committee for Advanced Therapies.
Dr. Patrick Celis (CAT Secretariat European Medicines Agency, UK)
Update on Regulatory Aspect of Regenerative Medical Products in Japan.
Dr. Masakazu Hirata (Pharmaceuticals and Medical Devices Agency)
New Zinc Finger Nuclease Architectures for Precision Genome Engineering
in the Development of T-cell and Hematopoietic Stem/Progenitor Cell Therapies
Dr. Michael C. Holmes (Sangamo Therapeutics, Inc., USA)
CTL019 Project in Japan and United States
Dr. Christopher Keir (Novartis Oncology, USA)
Gene Modified T Cell Therapy in Japan
Mr. Masanobu Kimura (Takara Bio Inc)
17:40-18:10

Oral Presentation from Poster Presentation

Reception
Saturday, 20 May, 2017
8:00-9:40
Plenary Session II "New Horizon of Stem Cell Transplantation"
Placenta-derived decidual stromal cells a novel therapy for severe acute graft-versus-host disease
Dr. Olle Ringden
(Laboratory Medicine, Karolinska Institutet Translational Cell Therapy Research group, Sweden)
Engineering Immune Cells from Cord Blood
Dr. Catherine M. Bollard (Children's National Medical Center, George Washington University, USA)
New Aspects of Haploidentical Transplantation Targeting Hematological Malignancies
Dr. Takanori Teshima (Hokkaido University)
New Aspects of Cord Blood Transplantation Targeting Hematological Malignancies
Dr. Satoshi Takahashi (Institute of Medical Science, The University of Tokyo)
9:40-10:20
Special Lecture IV
Gene Therapy for Hemophilia
Dr. Katherine A.High (Spark Therapeutics, USA)
10:20-10:30 Break
10:30-12:10
JSH-ASH Joint Session Next Generation of Cell and Gene Therapy
Therapeutic TCR Mimic Monoclonal Antibodies to Intracellular Oncogenic Proteins.
Dr. David A. Scheinberg (Memorial Sloan Kettering Cancer Center, USA)
Advances in CAR T Cell Therapy for Multiple Myeloma
Dr. Alfred Garfall (Perelman School of Medicine, University of Pennsylvania, USA)
Regeneration of T helper-like Cells that Induces Cytotoxic T cell-Mediated Antitumor Immunity
Dr. Shin Kaneko (CiRA Kyoto University)
Systemic and Potent Dendritic Cell (DC) Activation Modulates the Tumor Microenvironment and Shapes the Long-lived Tumor Specific Memory CD8+T Cells
Dr. Shin-ichiro Fujii
(Laboratory for Immunotherapy, RIKEN Center for Integrative Medical Sciences , RIKEN)
12:10-12:20 Break
12:20-13:20

Luncheon Seminar 3
(Co-sponsored by Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb K.K.)

Dr. Koji Izutsu (Department of Hematology, National Cancer Center Hospital)

12:20-13:20

Luncheon Seminar 4 (Co-sponsored by Novartis Pharma K.K.)

Dr. Hiroshi Fujiwara (Ehime University Hospital)